Clinical trial · Interventional
Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Ciprofol is a new anesthetic, which combines with γ- Aminobutyric acid-a (GABAA) receptor. Ciprofol has shown equivalent anesthetic efficacy of propofol at 1/4 to 1/5 of the dosage. Ciprofol has the pharmacodynamic characteristics of rapid onset, stable and rapid recovery. Phase III clinical results showed that the incidence of injection pain and respiratory and circulatory depression of ciprofol was lower than that of propofol. Therefore, ciprofol has a good application prospect in sedation for gastrointestinal endoscopy, especially for obese patients. In the current study, we would explore the proper dose of Ciprofol in sedated gastrointestinal endoscopy in obese patients.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Gastric Ulcer | — | UNRESOLVED | — |
| Intestinal Cancer | Malignant Intestinal Neoplasm | ALIAS | 0.90 |
| Intestinal Polyps | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ciprofol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Ciprofol group
- interventionNames
- Drug: ciprofol
Primary outcomes (1)
- measure
- Calculating the the median effective dose (ED50) of ciprofol for sedation gastrointestinal endoscopy in obese patients.
- timeFrame
- Patients will be followed for the duration of hospital stay, an expected average of 2 hours
Secondary outcomes (1)
- measure
- Calculating the the ED95 of ciprofol for sedation gastrointestinal endoscopy in obese patients.
- timeFrame
- Patients will be followed for the duration of hospital stay, an expected average of 2 hours
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age, ≤18 and ≤60 years, no gender limit 2. Undergoing routine gastrointestinal endoscopic diagnosis and treatment 3. American Society of Anesthesiologists (ASA) classification I-II 4. Body Mass Index(BMI) ≥28kg/m\^2 5. Clearly understand and voluntarily participate in the study; provide signed informed consent Exclusion Criteria: 1. Unhealthy alcohol drinking, defined by more than three standard drinks per day (≈10 g alcohol , equivalent to 50 g of strong Chinese spirits) 2. Drug abuse history within 3 months before the screening period 3. People who are known to be allergic to eggs, bean products, opioids and other drugs, propofol, etc 4. The researcher believes that patients should not participate in this trial
References
Publications (0)
Data not yet available